Journal
ADVANCED SCIENCE
Volume 9, Issue 33, Pages -Publisher
WILEY
DOI: 10.1002/advs.202203949
Keywords
breast cancer; cell-free nucleic acid; chemotherapy; metastasis; nanocarrier; scavenger
Categories
Funding
- U.S. DOD [W81XWH1910463, W81XWH1910464]
- U.S. NIH [RO1AR073935, F31CA257399, P30-CA013696, TL1-TR001875]
- National Natural Science Foundation of China [82002776]
- Medical Scientific Research Foundation of Guangdong Province, China [B2019094]
- U.S. Department of Defense (DOD) [W81XWH1910463, W81XWH1910464] Funding Source: U.S. Department of Defense (DOD)
Ask authors/readers for more resources
Polymeric nanoparticles that deliver chemotherapeutics and scavenge proinflammatory factors simultaneously are developed to inhibit chemotherapy-induced breast cancer metastasis. In mouse models, these nanoparticles reduce inflammatory cytokines and inhibit primary tumor growth and metastasis without significant side effects.
Chemotherapy, although effective against primary tumors, may promote metastasis by causing the release of proinflammatory factors from damaged cells. Here, polymeric nanoparticles that deliver chemotherapeutics and scavenge proinflammatory factors simultaneously to inhibit chemotherapy-induced breast cancer metastasis are developed. The cationic nanoparticles can adsorb cell-free nucleic acids (cfNAs) based on charge-charge interaction, which downregulates the expression of Toll-like receptors and then reduces the secretion of inflammatory cytokines. Through in vitro structural optimization, cationic polyamidoamine (PAMAM) dendrimers modified with drug-binding dodecyl groups and diethylethanolamine surface groups (PAMAM-G3-C12(5)-DEEA(20)) exhibit the most desirable combination of nanoparticle size (approximate to 140 nm), drug loading, cytotoxicity, cfNA binding, and anti-inflammatory activity. In the mouse models of breast cancer metastasis, paclitaxel-loaded nanoparticles reduce serum levels of cfNAs and inflammatory cytokines compared with paclitaxel treatment alone and inhibit both primary tumor growth and tumor metastasis. Additionally, no significant side effects are detected in the serum or major organs. These results provide a strategy to deliver chemotherapeutics to primary tumors while reducing the prometastatic effects of chemotherapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available